STAT News

STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

When it comes to rare disease treatments, patients often confront a difficult risk-benefit calculus. Such is the case with a therapy from Neurocrine Biosciences.

作者 STAT News

1 分钟阅读
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk
STAT+: Neurocrine Biosciences and the delicate balance of benefit and risk

有活动行业的新闻要分享吗?

提交新闻稿或信息,触达数千名活动行业专业人士。

联系我们→

更多Health Tech相关内容

相关洞察